Interaction between Pasteurella haemolytica, sulfadiazine/trimethoprim, and bovine viral diarrhea virus.
A study was designed to develop and define a sc tissue chamber as a suitable device for establishing a soft-tissue infection model in cattle and to use this model to study the interaction between Pasteurella haemolytica, sulfadiazine/trimethoprim, and bovine viral diarrhea virus (BVDV). Thermoplastic tissue chambers were implanted in the paralumbar fossae of 20 calves. At 35 days after implantation, calves were allotted to 4 groups of equal size and the calves in 2 groups were inoculated intratracheally with a New York-1 strain of BVDV. At 45 days after implantation, all chambers were inoculated with a 6-hour culture of P haemolytica serotype 1. Starting 36 hours after bacterial inoculation, sulfadiazine/trimethoprim was administered IV once a day to half of the virus-inoculated calves and to half of those calves that had not been exposed to virus. Inoculation of P haemolytica into tissue chambers resulted in the establishment of a localized soft-tissue infection, characteristic of pneumonic pasteurellosis. Despite the maintenance of chamber antimicrobial concentrations that exceeded minimal bactericidal concentrations established in vitro, the infections were not sterilized. This lack of efficacy was associated with decreased pH and increased protein concentrations in chamber fluids after inoculation. Infection with BVDV, which is thought to depress host defenses, had no effect on the response of P haemolytica to sulfadiazine/trimethoprim administration. Observation of responsive antibody titers, bacterial phagocytosis, and high leukocyte viability within P haemolytica-infected chambers documented functional host defenses within tissue chambers.
Clarke
C R
CR
Department of Veterinary Physiology, Pharmacology and Toxicology, School of Veterinary Medicine, Louisiana State University, Baton Rouge 70803.
Short
C R
CR
Corstvet
R E
RE
Nobles
D
D
D000818:Animals; D001912:Bovine Virus Diarrhea-Mucosal Disease / Q000150:complications* / Q000382:microbiology; D002417:Cattle; D002418:Cattle Diseases / Q000188:drug therapy* / Q000382:microbiology; D002470:Cell Survival; D015194:Diffusion Chambers, Culture; D004338:Drug Combinations / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006863:Hydrogen-Ion Concentration; D007958:Leukocyte Count; D007962:Leukocytes / Q000502:physiology; D010325:Pasteurella / Q000187:drug effects / Q000302:isolation & purification; D010326:Pasteurella Infections / Q000150:complications / Q000188:drug therapy / Q000382:microbiology / Q000662:veterinary*; D013411:Sulfadiazine / Q000494:pharmacology / Q000627:therapeutic use*; D014295:Trimethoprim / Q000494:pharmacology / Q000627:therapeutic use*; D000096926:Benzenesulfonamides
D004338:Drug Combinations; D013411:Sulfadiazine; D014295:Trimethoprim; C024873:sulfadiazine, trimethoprim drug combination; D000096926:Benzenesulfonamides